Clinical and epidemiological features of myasthenia gravis in Chilean population

Cea, Gabriel; Martínez, Diana; Salinas, Rodrigo; Vidal, Carolina; Hoffmeister, Lorena; Stuardo, A

doi:10.1111/ane.12967

Cited by 13 publications

(11 citation statements)

References 29 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We report the PR of symptomatic MG of 22.65 per 100,000. It is higher than that in previous studies using pyridostigmine databases, with PR ranging from 8.36 to 13.1 per 100,000 [6, 7, 14, 25, 26], but within the range of those reported in the epidemiological MG studies using other case collection methods (between 7.7 and 32.0 per 100,000) [5, 11, 15, 17, 18, 23, 27-30]. It may reflect a trend towards higher PRs, noted in most recent studies.…”

Section: Discussioncontrasting

confidence: 62%

Myasthenia Gravis in Poland: National Healthcare Database Epidemiological Study

Sobieszczuk

Napiórkowski²,

Szczudlik

et al. 2021

Neuroepidemiology

View full text Add to dashboard Cite

Introduction: Myasthenia gravis (MG) is a rare autoimmune disorder of the neuromuscular junction. MG epidemiology has not been studied in Poland in a nationwide study before. Methods: Our epidemiological data were drawn from the National Health Fund (Narodowy Fundusz Zdrowia, NFZ) database; an MG patient was defined as a person who received at least once medical service coded in ICD-10 as MG (G70) and at least 2 reimbursed prescriptions for pyridostigmine bromide (Mestinon®) or ambenonium chloride (Mytelase®) in 2 consecutive years. Results: On 1st of January 2019, 8,702 patients with MG were receiving symptomatic treatment (female:male ratio: 1.65:1). MG incidence was 2.36/100,000. The mean age of incident cases in 2018 was 61.37 years, 59.17 years for women and 64.12 years for men. Incidence of early-onset MG (<50 years) was 0.80/100,000 and 4.98/100,000 for late-onset MG (LOMG), with male predominance in LOMG. Prevalence was 22.65/100,000. In women, there was a constant increase in prevalence of symptomatic MG from the first decade of life up to 80–89 years. In men, an increase in prevalence appeared in the 6th decade. The highest prevalence was observed in the age group of 80–89 years: 59.65/100,000 in women and 96.25/100,000 in men. Conclusions: Our findings provide information on epidemiology of MG in Poland and can serve as a tool to evaluate healthcare resources needed for MG patients.

show abstract

Section: Discussioncontrasting

confidence: 62%

Myasthenia Gravis in Poland: National Healthcare Database Epidemiological Study

Sobieszczuk

Napiórkowski²,

Szczudlik

et al. 2021

Neuroepidemiology

View full text Add to dashboard Cite

show abstract

“…Worldwide prevalence is 1.5–17.9 per 100,000 and incidence 0.3–3 per 100,000 1,2 . The estimated prevalence of MG in Chile is 8.39 per 100,000 3 . Clinically, MG is characterized by weakness and excessive muscle fatigue.…”

Section: Introductionmentioning

confidence: 99%

Validation of Spanish version of 15‐item myasthenia gravis quality‐of‐life questionnaire

et al. 2021

Self Cite

View full text Add to dashboard Cite

Objectives The aim of this study was to achieve the translation and cross‐cultural adaptation of the MG‐QOL15R questionnaire into Spanish and the analysis of its psychometric properties. Materials and Methods We recruited patients with MG, ≥18 years old, whose mother tongue was Spanish. After the translation and cross‐cultural adaptation of the MG‐QOL15‐R, the following tests were performed: internal consistency using the Cronbach‐α coefficient and corrected item‐total correlations; reproducibility with a test‐retest analysis using intraclass correlation coefficients; and concurrent validity using Spearman's correlation coefficient of the Spanish language MG‐QOL15R‐S, Myasthenia Gravis Activity of Daily Living (MG‐ADL) and Quantitative Myasthenia Gravis (QMG) scores. As an approximation to construct validity, the nonparametric Mann‐Whitney U test was performed between MG‐QOL15R‐S scores according to the Myasthenia Gravis Foundation of America classification. Results A total of 83 MG patients were enrolled, mean age 48.19 ± 17.25 years; 58 (69.9%) were women. The mean MG‐QOL15R‐S score was 11.3 ± 7.1. Cronbach‐α coefficient was 0.92. Item‐total correlation ranged between 0.43 and 0.75. Intraclass correlation coefficient was 0.80. The Spearman correlation coefficient was 0.637 (p‐value < .001) for MG‐ADL and 0.487 (p‐value < .001) for QMG. Mann‐Whitney U tests of the mean MG‐QOL15R‐S scores were significantly different according to the clinical severity (p‐value < .001). Conclusions The Spanish version of the MG‐QOL15R is a valid and reliable instrument and potentially useful for measuring health‐related quality of life in Spanish‐speaking MG patients.

show abstract

“…Previous nationwide studies reported percentage of patients ever treated with CS or other IS ranging from 42% to 90% for CS and 28.1%–43% for other IS, with the highest rates reported in voluntary, patient‐submitted database 6‐10 . In our previous hospital‐based registry study, 11 the proportion of patients ever treated with CS was 57.2%, and 41.5% had no history of CS use.…”

Section: Discussionmentioning

confidence: 76%

Myasthenia gravis—treatment and severity in nationwide cohort

Sobieszczuk¹,

Napiórkowski

Szczudlik³

et al. 2022

Acta Neuro Scandinavica

View full text Add to dashboard Cite

Introduction Myasthenia gravis (MG) is a rare autoimmune disorder of neuromuscular junction. MG healthcare burden has not been studied in Poland before. Methods Data were drawn from the National Health Fund database; MG patient was defined as a person who received at least once medical service with ICD‐10 code MG (G70) and at least two reimbursed prescriptions for pyridostigmine bromide or ambenonium chloride in two consecutive years. We have analyzed treatment: immunosuppression, intravenous immunoglobulins (IVIg), plasma exchange (PE), the number and length of hospitalizations (LOS), intensive care unit (ICU) care, and deaths between 2013 and 2018. Results In 2018, there were 9012 MG patients (F:M 1.62:1), and 30.6% had early ‐onset MG (<50 years). 66.3% received symptomatic treatment only, 33.7%—glucocorticoids (CS) and/or other immunosuppressants (IS), 64.6%—CS only, 17.5%—azathioprine plus CS, 11%—azathioprine only, 4.6%—CS plus other IS (methotrexate, mycophenolate mofetil, cyclosporine, or tacrolimus), and 2%—other IS only. In 2018, 42.3% of patients were hospitalized at least once (mean 2.05/year), 13.7% due to MG (1.47/year). In 2018, 1.63% patients received PE, 2.33% IVIg. In 2013–2018, 2.7%–3.2% of MG patients required hospitalization in ICU. ICU mean LOS 2013–2018 was 11.5–15.0 days/per patient/year. 2.1% of all MG patients had myasthenic crisis. Mean age at death was 75.7 years for MG and 73.9 for general population (p = .006). All‐cause mortality was higher for men (4.1%–5.1%) than for women (2.5%–3.1%), p < .01. Conclusions Our findings confirm significant healthcare burden of MG, comprising a tool to plan resources needed for MG patients.

show abstract

Clinical and epidemiological features of myasthenia gravis in Chilean population

Abstract: This study reduces the gap in information about MG in South America. The prevalence of MG in Chile is within the range described worldwide. We did not see an increase in male frequency in the older age of onset group and thymoma was more frequent in the fifth and sixth decades.

Cited by 13 publications

References 29 publications

Myasthenia Gravis in Poland: National Healthcare Database Epidemiological Study

Myasthenia Gravis in Poland: National Healthcare Database Epidemiological Study

Validation of Spanish version of 15‐item myasthenia gravis quality‐of‐life questionnaire

Myasthenia gravis—treatment and severity in nationwide cohort

Contact Info

Product

Resources

About